ストックスクリーナーアプリを入手
2.845
0.34%
0.035
前日終値:
$2.88
開ける：
$2.9
24時間の取引高:
7,701
Relative Volume:
0.03
時価総額：
$77.70M
収益：
-
当期純損益:
$-49.81M
株価収益率:
-1.3196
EPS:
-2.156
ネットキャッシュフロー:
$-42.93M
1週間 パフォーマンス:
+11.15%
1か月 パフォーマンス:
+27.31%
6か月 パフォーマンス:
-37.72%
1年 パフォーマンス:
-81.20%
1日の値動き範囲:
$2.8508
$2.91
1週間の範囲:
$2.53
$3.05
52週間の値動き範囲:
$1.60
$15.83
Alto Neuroscience Inc Stock (ANRO) Company Profile
名前
Alto Neuroscience Inc
セクター
電話
773-255-5012
住所
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
ANRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
2.87 | 69.85M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.50 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.96 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.62 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.15 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-23 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-09-03 | 開始されました | Wedbush | Outperform |
| 2024-02-27 | 開始されました | Jefferies | Buy |
| 2024-02-27 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-27 | 開始されました | Stifel | Buy |
| 2024-02-27 | 開始されました | TD Cowen | Outperform |
| 2024-02-27 | 開始されました | William Blair | Outperform |
すべてを表示
Alto Neuroscience Inc (ANRO) 最新ニュース
Biotech Bargain Or Bust? Alto Neuroscience Faces Trial Test - Finimize
What makes Alto Neuroscience Inc. stock price move sharplyROI Focused Stock Calls - beatles.ru
Why Alto Neuroscience Inc. stock attracts strong analyst attentionFree Consultation - Newser
How Alto Neuroscience Inc. stock performs during market volatilityFree Stock Market Trend Analysis - Newser
Alto Neuroscience reprices employee stock options to $2.35 per share - Investing.com
Alto Neuroscience to advance depression drug after promising study By Investing.com - Investing.com South Africa
Alto Neuroscience (NYSE:ANRO) Receives Buy Rating from HC Wainwright - Defense World
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients - MarketScreener
Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results - TipRanks
Bank of America Corp DE Buys 22,007 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience : Corporate Presentation - marketscreener.com
Two Sigma Investments LP Has $130,000 Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright Affirms Buy Rating on Alto Neuroscience (ANRO), Sets $10 PT - MSN
Jane Street Group LLC Increases Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Wellington Management Group LLP Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Consensus Target Price from Analysts - Defense World
Nuveen Asset Management LLC Reduces Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright maintains buy rating on Alto Neuroscience stock By Investing.com - Investing.com Canada
Alto Neuroscience acquires novel TRD treatment candidate By Investing.com - Investing.com South Africa
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal - Yahoo
Alto Neuroscience, Inc. acquired Novel Dopamine Agonist Combination Product Candidate from Chase Pharmaceuticals Corporation, Inc. - MarketScreener
Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc. - TipRanks
Alto Neuroscience Acquires Assets from Chase Therapeutics - TipRanks
Alto Neuroscience acquires dopamine agonist combination candidate - TipRanks
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - Yahoo Finance
BNP Paribas Financial Markets Has $180,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience reports progress in depression drug trials By Investing.com - Investing.com South Africa
Alto Neuroscience, Inc. Presents Data At the 2025 American Society of Clinical Psychopharmacology Annual Meeting - marketscreener.com
Alto Neuroscience reports progress in depression drug trials - Investing.com India
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder - Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Northern Trust Corp Acquires 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
HC Wainwright Issues Pessimistic Outlook for ANRO Earnings - Defense World
Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating - TipRanks
Equities Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Wedbush Reiterates Neutral Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience Advances Precision Psychiatry Pipeline - TipRanks
Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights - marketscreener.com
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Average Target Price from Brokerages - Defense World
Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Trading Day Triumph: Alto Neuroscience Inc (ANRO) Ends at 2.17, a -0.91 Surge/Plunge - DWinneX
ANROAlto Neuroscienc Latest Stock News & Market Updates - Stock Titan
Alto Neuroscience Inc (ANRO) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.10%
大文字化:
|
ボリューム (24 時間):